Skip to main content
ABL Bio Inc. logo

ABL Bio Inc. — Investor Relations & Filings

Ticker · 298380 ISIN · KR7298380007 LEI · 9884007BRC71Y64NK235 KO Professional, scientific and technical activities
Open in API
Filings indexed 369 across all filing types
Latest filing 2020-12-14 Regulatory Filings
Country KR South Korea
Listing KO 298380

About ABL Bio Inc.

https://www.ablbio.com

ABL Bio Inc. is a clinical-stage biotechnology company specializing in the development of bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases. The company leverages several proprietary platforms. For central nervous system disorders, its 'Grabody-B' technology is a blood-brain barrier (BBB) penetrating shuttle designed to enhance drug delivery to the brain. In immuno-oncology, ABL Bio develops 4-1BB based bispecific antibodies aimed at minimizing toxicity and overcoming resistance to existing immunotherapies. The company is also advancing a pipeline of antibody-drug conjugates (ADCs) with an improved therapeutic index for conditions such as rare blood cancers. ABL Bio actively progresses its therapeutic candidates through clinical development.

Recent filings

Filing Released Lang Actions
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the closure of the shareholder register for the purpose of determining shareholders eligible to vote at the upcoming Annual General Meeting. It does not contain the full meeting materials or proxy statements, but rather serves as a formal notice of a corporate action related to shareholder rights and meeting preparation. Given its nature as a regulatory notification of a specific corporate event, it fits best under the RNS category.
2020-12-14 Korean
분기보고서 (2020.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for ABL Bio Inc. for the third quarter of 2020. It contains detailed financial information, business descriptions, management discussions, and capital structure data, which is characteristic of a comprehensive interim financial report. It is not an announcement or a short summary, but the full report itself. 9M 2020
2020-11-16 Korean
기타경영사항(자율공시)(레고켐바이오의 CStone Pharmaceuticals 기술이전 수익 배분 건)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from ABL Bio regarding a technology transfer agreement (licensing deal) between LegoChem Biosciences and CStone Pharmaceuticals. It details the financial terms, including upfront payments and milestone payments, and explains the profit-sharing arrangement between ABL Bio and LegoChem. Since this is a specific announcement of a business transaction/contractual agreement that does not fit into standard categories like earnings or dividends, it is classified as a general regulatory filing (RNS).
2020-10-29 Korean
기타경영사항(특허권취득)(자율공시)(DLL4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도 중국 특허 취득)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from ABL Bio regarding the acquisition of a patent in China. It is a voluntary disclosure ('자율공시') of a specific corporate event (patent acquisition). Since it does not fit into specific categories like M&A, financial reports, or director dealings, and is a standard regulatory announcement of a material event, it falls under the 'Regulatory Filings' category.
2020-10-23 Korean
기타경영사항(특허권취득)(자율공시)(항 α-syn 항체 및 그 용도)
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure ('자율공시') regarding the acquisition of a patent ('특허권 취득') by ABL Bio. It details the patent name, content, and utilization plan. Since this is a specific corporate announcement regarding a business development (patent acquisition) that does not fit into financial reporting, M&A, or governance categories, it falls under the general regulatory filing category.
2020-09-15 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding the scheduling of an Investor Relations (IR) event (기업설명회). It provides details such as the date, time, location (online conference call), purpose, and target audience. Since it is an announcement of an upcoming event rather than the presentation materials themselves, and it fits the criteria for a regulatory announcement regarding corporate activities, it is classified as a Regulatory Filing (RNS).
2020-09-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.